30,000 Heart Specialists Gather in Munich Today — The Hypothesis They Once Packed the Aisles For Stalled Last Month — Woody Magazine

We write the things that aren't news

30,000 Heart Specialists Gather in Munich Today — The Hypothesis They Once Packed the Aisles For Stalled Last Month

The drug lowered the inflammation number exactly as designed, and protected patients no better than a placebo. Cardiology has spent twenty years in the gap between those two sentences.

Science · Aug. 28, 2026 (Fri.)

In Three Lines

The world's largest cardiology congress opens today with a failed trial hanging over it. The news arrived four weeks ago.
The drug lowered its target inflammation marker right on schedule, and patients fared no better than on placebo. The same pattern has now appeared twice in two years.
What stalled is an experimental hypothesis, not a medicine on pharmacy shelves. Nothing here changes the evidence behind statins or colchicine.

Thirty thousand heart specialists arrive in Munich today for the annual congress of the European Society of Cardiology, the largest cardiology meeting in the world. Over four days, 59 major clinical trials will unveil their results for the first time. So far, an ordinary opening. What is not ordinary is the report card that arrived four weeks ago — and the twenty-year-old hypothesis that stalled in front of it.

Start with the report card. On July 31, Novo Nordisk — the Danish company behind Wegovy — released results from a cardiovascular trial it had been counting on. The candidate, ziltivekimab, was meant to be the company's next act after obesity. More than 6,300 patients with both heart disease and chronic kidney disease took the injection once a month. The drug did its job precisely. The inflammatory signal it targets quieted down, and the inflammation marker in patients' blood fell on schedule. Yet the combined rate of cardiovascular death, heart attack, and stroke matched the placebo group's. The hazard ratio came out at 0.99, which is the statistical spelling of "nothing happened." Novo's stock lost nearly a tenth of its value that day.

The drug succeeded, and the trial failed. If that sentence sounds wrong, the wrongness is worth following. It leads back twenty years.

For a long time, we believed cholesterol was the whole story, and it was never a foolish belief. Statins have prevented heart attacks on a scale few drugs can match. The trouble was the other half. Paul Ridker, a cardiologist at Harvard, kept returning to an awkward fact: roughly half of all heart attacks strike people whose cholesterol is not high. That means a second culprit. The leading suspect was inflammation — immune cells swarming the fatty deposits in an artery wall, swelling it until, one day, the wall ruptures.

Putting the suspect on trial required an instrument. Ridker chose hs-CRP, a protein the liver produces and releases into the blood whenever inflammation flares somewhere in the body. A high reading says that something, somewhere, is inflamed. In 2008, the JUPITER trial showed what the instrument could do. Nearly 18,000 people with normal cholesterol but elevated hs-CRP received either a statin or a placebo. The investigators stopped the trial early, before two years were up. Cardiovascular events in the statin group had fallen by almost half, and keeping the other half on a sugar pill had become hard to justify. One caveat, though. Statins lower cholesterol too, so JUPITER could not prove that taming inflammation saves hearts — only that people selected by their inflammation number respond remarkably well.

Proof required a drug that leaves cholesterol alone. Ridker's next instrument, canakinumab, was exactly that: an antibody used for rare inflammatory diseases, touching no lipids, silencing a single inflammatory signal. Ten thousand heart-attack survivors whose inflammation stayed high despite standard treatment joined the trial, and on August 27, 2017 — in Barcelona, at this very congress — the results came in. Delegates sat on the aisle floors; more queued outside the doors. Cardiovascular events fell 15 percent. Not a dazzling number, but it was earned without moving cholesterol at all — the first hard-outcome evidence that lowering inflammation alone protects the heart. "This is our 1994," Ridker told the room, invoking the year of the trial that launched the statin era. The inflammatory hypothesis seemed to have its era, too.

What followed looked scripted: the proven drug becomes a heart medicine, enters prescriptions, sets the new standard. A reasonable expectation. But canakinumab carried one fatal inconvenience. It was already on sale under another name, as a rare-disease therapy priced around $200,000 a year. Heart medicine is something millions of people take for life. To enter that market, Novartis would have had to cut its own price by as much as 98 percent. After the FDA declined the cardiovascular indication in 2018, the company withdrew its European application as well. The proof survived. The drug walked away.

An unlikely tenant filled the vacancy: colchicine, extracted from the autumn crocus and used against gout for thousands of years, with no patent and no pricing problem. Two trials — one in heart-attack survivors, one in patients with chronic coronary disease — showed clear reductions in cardiovascular events. In June 2023, the FDA approved the ancient pill under a title that reads like a milestone: the first anti-inflammatory cardiovascular therapy. At this point the story is tidy. Science opened the road, price blocked it, and a cheap old drug broke through. Through 2023, that is more or less how we told it.

The crack appeared the following year. The natural next step for colchicine was a bigger, stricter test, so Canadian investigators enrolled more than 7,000 patients immediately after a heart attack and followed them for three years. When the results landed in the fall of 2024, the lead investigator, Sanjit Jolly, said his team was "very surprised." Nothing had budged. The hazard ratio: 0.99. The strange part sat in the adjacent column. Three months in, the colchicine group's inflammation marker was measurably lower. The number went down. The events did not.

Then, last month, ziltivekimab received a report card with the same pattern, down to the identical hazard ratio of 0.99. The matching digits are a coincidence, of course. But when the two largest anti-inflammatory trials in two years stall at the same spot, the pattern gets hard to file under coincidence.

0.99

The hazard ratio shared by the largest colchicine trial (2024) and the ziltivekimab trial (2026) — meaning no different from placebo

To see why this happens, look again at what hs-CRP is. The protein is not the inflammation in the artery wall. When inflammation flares, immune cells release a signaling molecule called IL-6, and the liver reads that signal and manufactures hs-CRP in response. In automotive terms, hs-CRP is not the engine. It is the warning light on the dashboard. A wire runs from the engine to the panel, and the light glows at the end of that wire.

Now consider what ziltivekimab does. It is an antibody that blocks IL-6 — which is to say, it cuts the wire just before the bulb. That the warning light goes dark, that hs-CRP falls, is therefore less an achievement than a definition. The real question was whether cutting that wire changes the engine. For these patients, the answer was no.

There is an honest defense to make here. The field had reason to believe this wire was not bulb-only. People born with naturally weak IL-6 signaling suffer less heart disease over a lifetime, and that genetic evidence seemed to say the wire touches the engine too. That is why expectations ran high, and why the miss landed so hard. Ridker himself had put the caution in writing back in 2016: hs-CRP is a downstream gauge of what happens upstream, not a target in its own right.

So why did canakinumab work, and colchicine only half the time? The honest answer is that nobody knows precisely. The signal canakinumab cuts sits farther up the wire, close to where inflammation begins. Colchicine helped chronic patients and those about two weeks past their heart attack, and did nothing when started right after one. Inflammation, it turns out, is not a switch but a wiring panel. Which wire you cut, in whom, and when decides everything — and the dashboard light cannot tell those three apart. Cut any wire, and the light goes out just the same.

One thing deserves saying plainly. The two antibodies that stalled are not medicines in anyone's cabinet. Canakinumab was never sold as a heart drug, and ziltivekimab remains an experimental candidate. Statins are not casualties of this story but its most durable survivors, validated by decades of outcomes; this very congress features a major trial asking whether healthy people over 70 should start one. Colchicine's approval stands as well — what split was not the drug's standing but the timing and the patients. What stalled is not the medicine in a patient's hand. It is the assumption in a researcher's head.

Tomorrow morning, the next candidate takes the same stage: pacibekitug, another antibody pointed at the very same IL-6. Its interim numbers are dazzling — one arm, dosed just once a quarter, cut hs-CRP by more than 85 percent in the first ninety days. In fairness, this is a phase 2 trial, the stage built to confirm that a drug hits its target, so hs-CRP is the subject being graded by design. But we have just seen what a perfect score in that subject does and does not guarantee. The real answers come in 2027, when ziltivekimab reports from two further trials — one in heart failure, one begun right after heart attacks.

Twenty years ago, cardiology went looking for the culprit beyond cholesterol, and it genuinely found evidence against inflammation. That evidence still stands. What collapsed is the assumption stacked on top of it — that when the dashboard number falls, the engine has improved. The number fell, exactly as instructed. The patients stayed the same. This is the gap the thirty thousand in Munich sit down with this week. Moving a metric and changing an outcome are different jobs.

Sources & References

이 블로그 검색

Daily Woody

30,000 Heart Specialists Gather in Munich Today — The Hypothesis They Once Packed the Aisles For Stalled Last Month — Woody Magazine, Aug. 28, 2026

30,000 Heart Specialists Gather in Munich Today — The Hypothesis They Once Packed the Aisles For Stalled Last Month

댓글

댓글 쓰기

이 블로그의 인기 게시물

Daily Woody Essay | Jul 12, 2026 — SK Hynix Rings the Bell, and Tops Micron

Daily Woody Economy | Jun 26, 2026 (Fri) — KOSPI circuit breaker, Samsung & Hynix crater 9%

Daily Woody | Jul 13, 2026 — SK Hynix's Record-Setting $26.5B Nasdaq Debut